



Tokyo, December 6, 2024

FOR IMMEDIATE RELEASE

**Torii Files New Drug Application of TO-208
for the Treatment of Molluscum Contagiosum in Japan**

Torii Pharmaceutical Co., Ltd. (Torii) (TSE:4551) announced today that Torii has filed a New Drug Application for TO-208 in molluscum contagiosum on December 6, 2024.

Torii signed an exclusive license agreement with Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq:VRCA) for the development and commercialization of Verrica's product candidate for the treatment of molluscum contagiosum and common warts VP-102 (TO-208) in Japan on March 17, 2021.

TO-208 is a skin disease treatment drug containing cantharidin as an active ingredient. In the Phase 3 clinical studies of TO-208 in patients with molluscum contagiosum (≥ 2 years old) in Japan, the primary endpoint of efficacy has met superiority to the vehicle. Furthermore, the safety of TO-208 was confirmed and there were no observed issues of tolerability for the application. Torii expects TO-208 to be a new option for the treatment of molluscum contagiosum patients in Japan.

Separately, Verrica received approval of YCANTH® (VP-102) in July, 2023 for the topical treatment of molluscum contagiosum in adult and pediatric patients (≥ 2 years old) and is currently distributed only in the US since August, 2023. Verrica is in process of developing VP-102, an investigational product, for the treatment of common warts.

ABOUT Molluscum Contagiosum

Molluscum contagiosum is a highly prevalent, contagious dermatologic disease that often occurs in children due to infection with the molluscum contagiosum virus, a member of the poxviridae family, and is commonly referred to as "water warts." Many shiny papules with a diameter of 1 to 4 mm are seen on the trunk and extremities.

ABOUT Common Warts

Common warts (*Verruca vulgaris*) is a common dermatologic disease caused by infection with the human papillomavirus, and is commonly called "warts". Keratinized raised lesions measuring several mm to 1 cm are seen mainly on the hands and feet.

Contact for Torii Pharmaceutical Co., Ltd.:
Corporate Planning Department
(Public Relations)
Torii Pharmaceutical Co., Ltd.
Tokyo: +81-3-3231-6814
E-mail: webmaster@torii.co.jp